Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10-15 mg induce large, sustained reductions in body weight and waist circumference in adults with obesity without diabetes, significantly outperforming lifestyle interventions alone.
For individuals with obesity who have not achieved sustained weight loss through lifestyle changes alone, adding once-weekly semaglutide (2.4 mg) or tirzepatide (10-15 mg) to a lifestyle program can result in significant, clinically meaningful weight loss (12-19%) and waist circumference reduction. These treatments are generally well-tolerated, with side effects typically being mild gastrointestinal issues that diminish over time.
This emphasizes that once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well-tolerated.
Why this rating
Based on a systematic review and meta-analysis of 7 randomized controlled trials (n=5140) with low risk of bias.
Source
Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Alberte Laura Oest Müllertz et al. · Obesity Reviews · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →